Xia R - Search Results

1

Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.

Zhou Y, Xia R, Xiao H, Pu D, Long Y, Ding Z, Liu J, Ma X. Zhou Y, et al. Among authors: xia r. Int Immunopharmacol. 2021 Feb;91:107296. doi: 10.1016/j.intimp.2020.107296. Epub 2020 Dec 23. Int Immunopharmacol. 2021. PMID: 33360368

2

Clinical features, treatment, and prognosis of different histological types of primary small bowel adenocarcinoma: A propensity score matching analysis based on the SEER database.

Zhou YW, Xia RL, Chen YY, Ma XL, Liu JY. Zhou YW, et al. Eur J Surg Oncol. 2021 Aug;47(8):2108-2118. doi: 10.1016/j.ejso.2021.03.260. Epub 2021 Apr 2. Eur J Surg Oncol. 2021. PMID: 33849741

3

Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments.

Xia R, Zhou Y, Wang Y, Yuan J, Ma X. Xia R, et al. Front Oncol. 2021 Apr 12;11:633916. doi: 10.3389/fonc.2021.633916. eCollection 2021. Front Oncol. 2021. PMID: 33912455 Free PMC article. Review.

4

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development.

Cheng K, Wang Y, Zhou Y, Xia R, Tang L, Liu J. Cheng K, et al. Among authors: xia r. Clin Med Insights Oncol. 2021 Nov 24;15:11795549211056261. doi: 10.1177/11795549211056261. eCollection 2021. Clin Med Insights Oncol. 2021. PMID: 34866959 Free PMC article. Review.

5

Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Zhou YW, Xu Q, Wang Y, Xia RL, Liu JY, Ma XL. Zhou YW, et al. Int J Ophthalmol. 2022 Apr 18;15(4):646-656. doi: 10.18240/ijo.2022.04.19. eCollection 2022. Int J Ophthalmol. 2022. PMID: 35450191 Free PMC article. Review.

6

Epidemiology, Treatment, and Outcome of Pancreatic Squamous Cell Carcinoma and Pancreatic Adenocarcinoma: A Propensity Score-Matching Analysis Based on SEER-Database.

Wang Y, Zhou Y, Chen Y, Xia R, Liu J. Wang Y, et al. Among authors: xia r. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221106533. doi: 10.1177/15330338221106533. Technol Cancer Res Treat. 2022. PMID: 35770310 Free PMC article.

7

The role of Hedgehog and Notch signaling pathway in cancer.

Xia R, Xu M, Yang J, Ma X. Xia R, et al. Mol Biomed. 2022 Dec 15;3(1):44. doi: 10.1186/s43556-022-00099-8. Mol Biomed. 2022. PMID: 36517618 Free PMC article. Review.

8

Immunotherapy or antiangiogenic therapy plus chemotherapy as first-line treatment of patients with PD-L1(-) advanced non-squamous non-small cell lung cancer in a Chinese cohort.

Xia R, Li Y, Yang L, Huang M. Xia R, et al. Cancer Med. 2023 Jul;12(13):14282-14292. doi: 10.1002/cam4.6101. Epub 2023 May 22. Cancer Med. 2023. PMID: 37212483 Free PMC article.

9

Targeting the tumor stroma for cancer therapy.

Xu M, Zhang T, Xia R, Wei Y, Wei X. Xu M, et al. Among authors: xia r. Mol Cancer. 2022 Nov 2;21(1):208. doi: 10.1186/s12943-022-01670-1. Mol Cancer. 2022. PMID: 36324128 Free PMC article. Review.

10

Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting.

Xu M, Wang Y, Xia R, Wei Y, Wei X. Xu M, et al. Among authors: xia r. Cell Prolif. 2021 Oct;54(10):e13115. doi: 10.1111/cpr.13115. Epub 2021 Aug 31. Cell Prolif. 2021. PMID: 34464477 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,687 results

Search Page

Filters